Search clinical trials for: Camrelizumab(SHR-1210)

Total 3114 results

Shanghai Zhongshan Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)

Gastric Adenocarcinoma

China
Shanghai Chest Hospital

Not yet recruiting

Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）

Esophageal Squamous Cell Carcinoma

China
Guangdong Association of Clinical Trials

Not yet recruiting

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Non-Small-Cell Lung Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Breast Cancer

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (APFAO)

Toxicity | Overall Survival | Progression-free Survival | Clinical Benefit Rate

China
Cancer Hospital of Guangxi Medical University

Unknown

A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection

Hepatocellular Carcinoma

China
Henan Cancer Hospital
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

Esophageal Carcinoma | Lung Cancer, Nonsmall Cell

China
Sanjay Gandhi Postgraduate Institute of Medical...
Ram Manohar Lohia Institute of Medical Sciences, Lucknow

Terminated

Re-treatment of HCV Following DAA Failure

Chronic Hepatitis C

India
Henan Cancer Hospital

Unknown

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Advanced Cancer | Mucosal Melanoma | Apatinib | SHR-1210

China
Sun Yat-sen University

Unknown

Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC (SEQUENCE)

Non Small Cell Lung Cancer

China
Henan Cancer Hospital

Unknown

SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer

Triple-negative Breast Cancer
Di Wu

Recruiting

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Acral Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy (PASSION)

Small-cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Carcinoma, Non-Small-Cell Lung

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Classical Hodgkin Lymphoma

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Hepatocellular Carcinoma | Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Advanced Biliary Tract Carcinoma | Advanced Primary Liver Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Heike E Daldrup-Link

Completed

Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI (Osteosarcoma)

Bone Cancer | Osteosarcoma | Chondrosarcoma | Rhabdomyosarcoma | Bone Sarcoma | Osteomyelitis | Bone Necrosis | Ewing's Sarcoma

United States
The First Affiliated Hospital with Nanjing Medical...
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma (HCC-009)

Hepatocellular Carcinoma

China
Hangzhou Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma

Esophageal Neoplasms | Esophageal Diseases

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.; Peking University Shougang Hospital

Withdrawn

Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma

Progression | Pediatric Cancer | Effect of Drugs

China
Shandong Provincial Hospital

Unknown

Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (MWA in NSCLC)

NSCLC Stage IV

China
Manjunath Prakash Pai
Pfizer

Completed

Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects

Obesity

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Early Stage Non-small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Unknown

A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer

Esophageal Cancer

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma (SHR-1210)

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Unknown

SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

Hepatocellular Carcinoma

China
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
Chinese PLA General Hospital

Recruiting

The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer

BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma

China
Helios Albert-Schweitzer-Klinik Northeim

Completed

Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy (EC-Cap-SC)

Colorectal Polyps | Colorectal Adenomas

Germany, Poland
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer

Breast Cancer
ModernaTX, Inc.

Completed

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

Influenza | SARS-CoV-2 | RSV

United Kingdom, Australia, United States
Institute of Liver and Biliary Sciences, India

Recruiting

A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

Spontaneous Bacterial Peritonitis

India
Maimónides Biomedical Research Institute of Córdoba

Completed

Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical

Acinetobacter Infections
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.

Alzheimer's Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Asthma With Eosinophilic Phenotype

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

Primary Hypercholesterolemia

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Solid Tumor

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

Diabetic Foot | Bacterial Infections | Osteomyelitis

China, Colombia, Estonia, Denmark, Taiwan, France, United States, Canada, Spain, Belgium, Austria, Chile, Korea, Republic of, Mexico, Slovakia, United Kingdom, Russian Federation, Croatia, Turkey, Lithuania, Poland, Latvia, Finland, H... and more
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

H101 Combined With Camrelizumab for Recurrent Cervical Cancer

Uterine Cervical Neoplasms | Oncolytic Virotherapy | Camrelizumab

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

Alzheimer's Disease

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

Prevention of Graft Rejection After Organ Transplantation

China

Search clinical trials for: Camrelizumab(SHR-1210)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations